2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2019

Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity
Abstract Number: 1019

Involvement of Mast Cells in the Pathogenesis of Sjögren’s Syndrome By Induction of Tissue Fibrosis Via Fibroblast Collagen Synthesis
Abstract Number: 1020

Involvement of Toll-like-Receptor-9 Pathway on Natural Killer Cells in Systemic Lupus Erythematosus
Abstract Number: 1482

Is 14.3.3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?
Abstract Number: 1168

Is a Change in Physical Activity Associated with a Change in Health-Related Quality of Life after Total Knee Replacement?
Abstract Number: 1656

Is a Positive Family History of Spondyloarthritis Relevant for Diagnosing Axial Spondyloarthritis Once HLA-B27 Status Is Known? Data from the ASAS, DESIR, and SPACE Cohorts
Abstract Number: 639

Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Abstract Number: 2923

Is All MRI-SIJ Inflammation the Same? Gradient of Structural Damage with Increasing Cumulative Inflammation at the SIJ Quadrant Level in Axial Spondyloarthritis – 5-Year Data from the DESIR Cohort
Abstract Number: 1628

Is Axial Psoriatic Arthritis Distinct from Ankylosing Spondylitis with and without Concomitant Psoriasis?
Abstract Number: 2713

Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
Abstract Number: 1591

Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?
Abstract Number: 435

Is Frailty Associated with Worse Outcomes after Total Joint Replacements?
Abstract Number: 2782

Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
Abstract Number: 749

Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
Abstract Number: 2393

Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].